Autologous dnTGF-BRII-armored anti-GPC3 CAR T cells AZD5851

{
  "id": "MLC-T-ONC-011610",
  "term": "Autologous dnTGF-BRII-armored anti-GPC3 CAR T cells AZD5851",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3) and the dominant negative (dn) form of transforming growth factor-beta (TGF-beta; TGFb) receptor 2 (dnTGF-BRII; dnTGFbR2), with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, autologous dnTGF-BRII-armored anti-GPC3 CAR T cells AZD5851 are directed to and induce selective toxicity in GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed on normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation. The inclusion of dnTGF-BRII blocks the signaling of the immunosuppressive cytokine TGFb in the tumor microenvironment (TME) and makes the AZD5851 T cells resistant to TGFb. TGFb negatively regulates T-cell proliferation and activation and plays a key role in tumor immune suppression.",
  "synonyms": [
    "autologous anti-GPC3 CAR T cells AZD5851",
    "autologous armored GPC3 CAR-T cells AZD5851"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-dntgf-brii-armored-anti-gpc3-car-t-cells-azd5851/"
}